GlassScriptPhysician profile
Michel Skaf
NPI 1548764137
$14,109.79
in general payments reported to CMS, 2019-2025
10 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.78 · 2024: $629 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $7,576 · Travel and Lodging: $3,414 · Food and Beverage: $2,857 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $7,575.66 |
| Travel and Lodging | $3,413.78 |
| Food and Beverage | $2,857.08 |
| Education | $181.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,733.06 | 2024-2025 | Tacticath, Assurity, Cardiomems |
| Boston Scientific Corporation | $5,203.27 | 2025 | General - Therapies, Ingevity+, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $463.86 | 2024-2025 | Lifevest |
| Medtronic, INC. | $347.59 | 2024-2025 | Symplicity G3, Sphere-9 |
| Biosense Webster, INC. | $218.68 | 2025 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $63.95 | 2022 | |
| Biotronik INC. | $26.74 | 2025 | Solia |
| Philips North America LLC | $21.43 | 2025 | Lm Undivided |
| Lilly USA, LLC | $17.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.38 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Skaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.